At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 139 enrolled
Drug / intervention
FOLFOX + bevacizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating FOLFOX + bevacizumab and Vitamin D for Metastatic Colorectal Cancer. Completed, enrolled 139 participants across 18 sites.
Detailed Summary
This is a prospective, randomized, double-blind phase II trial to evaluate the efficacy and safety of two doses of vitamin D supplementation in combination with standard chemotherapy in participants with previously-untreated metastatic colorectal adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartApr 2012
Primary CompletionNov 2019
TodayJul 2026
First PostedJan 24, 2012
Enrollment StartApr 13, 2012
Primary CompletionNov 9, 2019
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 14.4 years ago
Interventions
FOLFOX + bevacizumabdrug
Vitamin Ddietary